A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder

References

• Hodgkins P, Arnold LE, Shaw M, et al. A systematic review of global publication trends regarding long-term outcomes of ADHD. Front Psychiatry. 2011;2:84.
   PubMedGoogle Scholar
• Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99.
   PubMed Web of Science ®Google Scholar
• Harpin V, Mazzone L, Raynaud JP, et al. Long-term outcomes of ADHD: a systematic review of self-esteem and social function. J Atten Disord. 2016;20:295–305.
   PubMed Web of Science ®Google Scholar
• Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005;90(Suppl 1):i2–i7.
   PubMed Web of Science ®Google Scholar
• Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics. 2004;114:e541–e547.
   PubMed Web of Science ®Google Scholar
• Loeber R, Burke JD, Lahey BB, et al. Oppositional defiant and conduct disorder: a review of the past 10 years, part I. J Am Acad Child Adolesc Psychiatry. 2000;39:1468–1484.
   PubMed Web of Science ®Google Scholar
• Goodman DW, Lasser RA, Babcock T, et al. Managing ADHD across the lifespan in the primary care setting. Postgrad Med. 2011;123:14–26.
   PubMed Web of Science ®Google Scholar
• Robb A, Findling R. Challenges in the transition of care for adolescents with attention deficit/hyperactivity disorder. Postgrad Med. 2013;125:131–140.
   PubMed Web of Science ®Google Scholar
• Turgay A, Goodman DW, Asherson P, et al. Lifespan persistence of ADHD: the life transition model and its application. J Clin Psychiatry. 2012;73:192–201.
   PubMed Web of Science ®Google Scholar
• Kooij JJS, Huss M, Asherson P, et al. Distinguishing comorbidity and successful management of adult ADHD. J Atten Disord. 2012;16(5 Suppl):3S–19S.
   PubMed Web of Science ®Google Scholar
• Bernfort L, Nordfeldt S, Persson J. ADHD from a socio-economic perspective. Acta Paediatr. 2008;97:239–245.
   PubMed Web of Science ®Google Scholar
• Wu E, Hodgkins P, Ben-Hamadi R, et al. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs. 2012;26:581–600.
   PubMed Web of Science ®Google Scholar
• King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess. 2006;10:iii–iv, xiii–146.
   PubMed Web of Science ®Google Scholar
• Faber A, Van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS Drugs. 2008;22:157–170.
   PubMed Web of Science ®Google Scholar
• Zupancic JA, Miller A, Raina P, et al. Part 3: economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disorder. In: Miller A, Lee SK, Raina P, editors. A review of therapies for attention-deficit/hyperactivity disorder. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment; 1998.
   Google Scholar
• Denchev P, Kaltman JR, Schoenbaum M, et al. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation. 2010;121:1329–1337.
   PubMed Web of Science ®Google Scholar
• Hummel S, Naylor P, Chilcott J, et al. Cost-effectiveness of universal interventions which aim to promote emotional and social wellbeing in secondary schools. ScHARR Public Health Evidence Report 1.2, 2009. [cited 2016 July 2]. Available from: https://www.sheffield.ac.uk/polopoly_fs/1.43296!/file/Schools-1_2.pdf
   Google Scholar
• Hernández Alava M, Popli G, Hummel S, et al. Economic outcomes of early years programmes and interventions designed to promote cognitive, social and emotional development among vulnerable children and families. Part 1 - Econometric analysis of UK longitudinal data sets. ScHARR Public Health Evidence Report 9.4, 2011. [cited 2016 July 2]. Available from: https://shef.ac.uk/polopoly_fs/1.190496!/file/preschoolEcon9_4.pdf
   Google Scholar
• Purshouse R, Brennan A, Latimer N, et al. Modelling to assess the effectiveness and cost-effectiveness of public health related strategies and interventions to reduce alcohol attributable harm in England using the Sheffield Alcohol Policy Model version 2.0 (Final Report), 2009. [cited 2016 July 2]. Available from: https://www.nice.org.uk/guidance/ph24/evidence/economic-modelling-report-371533357
   Google Scholar
• Alemi F, Taxman F, Baghi H, et al. Costs and benefits of combining probation and substance abuse treatment. J Ment Health Policy Econ. 2006;9:57–70.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Neeser K, Weiss C, et al. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol. 2000;35:478–492.
   PubMed Web of Science ®Google Scholar
• Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26:497–511.
   PubMed Web of Science ®Google Scholar
• Annemans L, Nackaerts K, Bartsch P, et al. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investig. 2009;29:655–665.
   PubMed Web of Science ®Google Scholar
• Orme ME, Hogue SL, Kennedy LM, et al. Development of the health and economic consequences of smoking interactive model. Tob Control. 2001;10:55–61.
   PubMed Web of Science ®Google Scholar
• Tran K, Asakawa K, Cimon K, et al. Pharmacologic-based strategies for smoking cessation: clinical and cost-effectiveness analyses. (Technology Report; no. 130), 2010. Ottawa: Canadian Agency for Drugs and Technologies in Health. [cited 2016 July 2]. Available from: https://www.cadth.ca/node/81039/
   Google Scholar
• Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6:1–245.
   Google Scholar
• Chisholm D, Sanderson K, Ayuso-Mateos JL, et al. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry. 2004;184:393–403.
   PubMed Web of Science ®Google Scholar
• Haji Ali Afzali H, Karnon J, Gray J. A proposed model for economic evaluations of major depressive disorder. Eur J Health Econ. 2012;13:501–510.
   PubMed Web of Science ®Google Scholar
• Soares-Weiser K, Bravo Vergel Y, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess. 2007;11:iii-iv, ix–206.
   Web of Science ®Google Scholar
• Revicki DA, Brown RE, Keller MB, et al. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry. 1997;58:47–58.
   PubMed Web of Science ®Google Scholar
• Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacol Bull. 1995;31:249–258.
   PubMedGoogle Scholar
• Valenstein M, Vijan S, Zeber JE, et al. The cost-utility of screening for depression in primary care. Ann Intern Med. 2001;134:345–360.
   PubMed Web of Science ®Google Scholar
• Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry. 1993;162:38–42.
   PubMed Web of Science ®Google Scholar
• Klein RG, Mannuzza S, Olazagasti MA, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry. 2012;69:1295–1303.
   PubMed Web of Science ®Google Scholar